Syra Health Corp. Class A Common Stock (SYRA) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Syra Health Corp. Class A Common Stock (SYRA) ein Healthcare-Unternehmen mit einer Bewertung von 0.
Zuletzt analysiert: 16. März 2026Syra Health Corp. Class A Common Stock (SYRA) Gesundheitswesen & Pipeline-Uebersicht
Syra Health Corp. delivers health education, population health management, and digital health solutions, targeting mental health facilities and government agencies. With a focus on telehealth and digital transformation, Syra operates in the evolving healthcare services sector, marked by a negative profit margin and high beta.
Investmentthese
Syra Health Corp. operates in the growing healthcare services market, with a focus on digital health and telehealth solutions. The company's diverse service offerings, including health education, population health management, and mental health services, position it to capitalize on the increasing demand for integrated healthcare solutions. Key value drivers include the expansion of its Syrenity telehealth platform and the growth of its digital health solutions. However, the company's negative profit margin of -12.4% and high beta of 3.96 indicate significant financial risk. The company's small market capitalization also presents liquidity concerns. Investors should carefully weigh the growth potential against the financial risks before considering an investment in Syra Health.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Syra Health Corp. operates with a market capitalization of $0.00B, indicating its status as a micro-cap company.
- The company's P/E ratio is -1.40, reflecting its current lack of profitability.
- Syra Health Corp. has a negative profit margin of -12.4%, highlighting challenges in achieving profitability.
- The company's gross margin is 29.8%, suggesting potential for improved profitability with efficient cost management.
- Syra Health Corp. has a high beta of 3.96, indicating significant volatility compared to the broader market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Diverse service offerings including health education, population health management, and digital health.
- Focus on telehealth and digital health solutions.
- Strong relationships with mental health hospitals and government agencies.
- Development of proprietary Syrenity telehealth platform.
Schwaechen
- Negative profit margin indicating financial challenges.
- Small market capitalization and limited financial resources.
- High beta indicating significant volatility.
- Limited brand recognition compared to larger competitors.
Katalysatoren
- Ongoing: Expansion of Syrenity telehealth platform to increase market reach and service offerings.
- Ongoing: Growth in digital health solutions to capitalize on the increasing adoption of digital healthcare technologies.
- Ongoing: Strategic partnerships with healthcare organizations to expand service delivery and customer base.
- Ongoing: Development and launch of new health education programs to improve patient outcomes and engagement.
- Ongoing: Expansion of healthcare staffing solutions to address the growing shortage of healthcare professionals.
Risiken
- Potential: Intense competition from larger, more established players in the healthcare services industry.
- Potential: Regulatory changes and healthcare reform that could impact the company's business model.
- Potential: Economic downturn that could reduce demand for healthcare services.
- Potential: Cybersecurity threats and data breaches that could compromise patient data and damage the company's reputation.
- Ongoing: Negative profit margin indicating financial challenges and potential liquidity issues.
Wachstumschancen
- Growth opportunity 1: Expansion of Syrenity Telehealth Platform: Syra Health's development of Syrenity, an on-demand telehealth platform for mental health services, presents a significant growth opportunity. The telehealth market is projected to reach $55.6 billion by 2027, driven by increasing demand for remote healthcare services. By expanding the features and reach of Syrenity, Syra Health can capture a larger share of this growing market and improve access to mental health services. Timeline: Ongoing.
- Growth opportunity 2: Digital Health Solutions: Syra Health's digital health solutions, including digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps, offer substantial growth potential. The digital health market is expected to reach $379 billion by 2024, fueled by the increasing adoption of digital technologies in healthcare. By developing innovative digital health solutions tailored to the needs of its clients, Syra Health can drive revenue growth and enhance its competitive position. Timeline: Ongoing.
- Growth opportunity 3: Healthcare Workforce Solutions: Syra Health's healthcare staffing solutions address the growing demand for qualified healthcare professionals. The healthcare staffing market is projected to reach $44.7 billion by 2027, driven by shortages of nurses, physicians, and other healthcare workers. By providing flexible and cost-effective staffing solutions, Syra Health can help healthcare organizations meet their workforce needs and improve patient care. Timeline: Ongoing.
- Growth opportunity 4: Population Health Management Services: Syra Health's population health management services, including analytics as a service, epidemiology, and health equity analytics solutions, offer a valuable service to healthcare organizations seeking to improve patient outcomes and reduce costs. The population health management market is expected to reach $69.2 billion by 2027, driven by the increasing focus on value-based care and preventative medicine. By providing data-driven insights and solutions, Syra Health can help healthcare organizations optimize their population health management strategies. Timeline: Ongoing.
- Growth opportunity 5: Health Education Services: Syra Health's health education services, including medical communications, patient education, and healthcare training, address the critical need for effective communication and education in healthcare. The health education market is expected to grow as healthcare organizations increasingly recognize the importance of patient engagement and adherence. By providing engaging and informative health education programs, Syra Health can help improve patient outcomes and satisfaction. Timeline: Ongoing.
Chancen
- Expansion of Syrenity telehealth platform to capture a larger share of the telehealth market.
- Growth of digital health solutions to meet the increasing demand for digital healthcare technologies.
- Expansion of healthcare staffing solutions to address the growing shortage of healthcare professionals.
- Leveraging population health management services to capitalize on the increasing focus on value-based care.
Risiken
- Intense competition from larger, more established players in the healthcare services industry.
- Regulatory changes and healthcare reform that could impact the company's business model.
- Economic downturn that could reduce demand for healthcare services.
- Cybersecurity threats and data breaches that could compromise patient data and damage the company's reputation.
Wettbewerbsvorteile
- Diverse service offerings provide a comprehensive suite of healthcare solutions.
- Focus on digital health and telehealth solutions positions the company for future growth.
- Strong relationships with mental health hospitals and government agencies.
- Proprietary Syrenity telehealth platform offers a competitive advantage.
Ueber SYRA
Syra Health Corp., established in 2020 and headquartered in Carmel, Indiana, is a healthcare services company that provides a suite of solutions, including health education, population health management, behavioral and mental health services, healthcare workforce solutions, and digital health services. The company's health education services encompass medical communications, patient education, and healthcare training programs. Its population health management services include analytics as a service, epidemiology, and health equity analytics solutions, designed to improve patient outcomes and reduce healthcare costs. Syra Health is also developing Syrenity, a telehealth platform focused on delivering mental health services on-demand. Furthermore, the company offers healthcare staffing solutions and digital health solutions, including digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. Syra Health serves a diverse clientele, including mental health hospitals, government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers, positioning itself as a versatile partner in the healthcare ecosystem.
Was das Unternehmen tut
- Provides health education services, including medical communications and patient education.
- Offers population health management services, such as analytics and epidemiology solutions.
- Develops Syrenity, an on-demand telehealth platform for mental health services.
- Provides healthcare staffing solutions to hospitals and healthcare organizations.
- Offers digital health solutions, including digital transformation and cloud security.
- Serves mental health hospitals, government agencies, and managed care entities.
Geschaeftsmodell
- Generates revenue through health education services provided to healthcare organizations.
- Earns revenue from population health management services, including data analytics and consulting.
- Monetizes its Syrenity telehealth platform through subscription fees and service charges.
- Derives income from healthcare staffing solutions provided to hospitals and clinics.
Branchenkontext
Syra Health Corp. operates within the healthcare services industry, which is experiencing significant growth due to factors such as an aging population, increasing prevalence of chronic diseases, and advancements in technology. The industry is characterized by intense competition, with companies vying for market share in areas such as telehealth, digital health, and population health management. Syra Health's focus on integrated healthcare solutions and its diverse service offerings position it to compete effectively in this dynamic landscape. However, the company faces challenges from larger, more established players with greater resources and brand recognition.
Wichtige Kunden
- Mental health hospitals and organizations seeking comprehensive healthcare solutions.
- Government agencies requiring population health management and health education services.
- Integrated health networks looking for digital health and telehealth solutions.
- Managed care entities seeking to improve patient outcomes and reduce healthcare costs.
- Pharmaceutical manufacturers requiring medical communications and patient education programs.
Finanzdaten
Chart & Info
Syra Health Corp. Class A Common Stock (SYRA) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Syra Health Q4 EPS $(0.01) Up From $(0.08) YoY, Sales $1.734M Down From $2.000M YoY.
benzinga · 12. März 2026
-
Syra Health Posts Strong FY2025 Results with 157% Population Health Growth and 76% Net Loss Reduction: Targets Profitability by Year-End 2026
prnewswire.com · 12. März 2026
-
Syra Health To Announce Fourth Quarter and Full Year 2025 Financial Results
prnewswire.com · 5. März 2026
-
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga · 20. Mai 2024
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer SYRA.
Kursziele
Wall-Street-Kurszielanalyse fuer SYRA.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von SYRA auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
Aktuelle Nachrichten
Syra Health Q4 EPS $(0.01) Up From $(0.08) YoY, Sales $1.734M Down From $2.000M YoY.
Syra Health Posts Strong FY2025 Results with 157% Population Health Growth and 76% Net Loss Reduction: Targets Profitability by Year-End 2026
Syra Health To Announce Fourth Quarter and Full Year 2025 Financial Results
12 Health Care Stocks Moving In Monday's Pre-Market Session
Neueste Syra Health Corp. Class A Common Stock-Analyse
Fuehrung: Gregory R. Alexander
Unknown
Information about Gregory R. Alexander's background is not available in the provided context. Therefore, his career history, education, and previous roles are unknown. Further research would be needed to provide a comprehensive biography.
Erfolgsbilanz: Information about Gregory R. Alexander's track record is not available in the provided context. Key achievements, strategic decisions, and company milestones under his leadership are unknown. Further research would be needed to evaluate his performance as CEO.
SYRA OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Syra Health Corp. may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases the risk of investing in Syra Health Corp.
- Lower trading volumes and wider bid-ask spreads can lead to price volatility and illiquidity.
- Lack of regulatory oversight on the OTC Other tier increases the potential for fraud and manipulation.
- Limited access to capital markets can hinder the company's ability to raise funds for growth and expansion.
- The OTC Other tier may attract speculative trading, increasing the risk of sudden price swings.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Consult with a financial advisor before investing.
- Check for any legal or regulatory issues involving the company.
- Understand the risks associated with investing in OTC stocks.
- Company incorporation in 2020 suggests a relatively new business.
- Headquarters located in Carmel, Indiana.
- Provides a range of healthcare services, including health education and digital health solutions.
- Serves mental health hospitals and government agencies.
Was Anleger ueber Syra Health Corp. Class A Common Stock (SYRA) wissen wollen
What are the key factors to evaluate for SYRA?
Evaluating SYRA involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Diverse service offerings including health education, population health management, and digital health.. Primary risk to monitor: Potential: Intense competition from larger, more established players in the healthcare services industry.. This is not financial advice.
How frequently does SYRA data refresh on this page?
SYRA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SYRA's recent stock price performance?
Recent price movement in Syra Health Corp. Class A Common Stock (SYRA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse service offerings including health education, population health management, and digital health.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SYRA overvalued or undervalued right now?
Determining whether Syra Health Corp. Class A Common Stock (SYRA) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SYRA?
Before investing in Syra Health Corp. Class A Common Stock (SYRA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SYRA to a portfolio?
Potential reasons to consider Syra Health Corp. Class A Common Stock (SYRA) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Diverse service offerings including health education, population health management, and digital health.. Additionally: Focus on telehealth and digital health solutions.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of SYRA?
Yes, most major brokerages offer fractional shares of Syra Health Corp. Class A Common Stock (SYRA) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SYRA's earnings and financial reports?
Syra Health Corp. Class A Common Stock (SYRA) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for SYRA earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data as of March 16, 2026.
- OTC market data may be limited or delayed.
- AI analysis is pending and may provide further insights.